0001562180-23-000249.txt : 20230105
0001562180-23-000249.hdr.sgml : 20230105
20230105202354
ACCESSION NUMBER: 0001562180-23-000249
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bailey John E. (Jack) Jr.
CENTRAL INDEX KEY: 0001806147
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38096
FILM NUMBER: 23513319
MAIL ADDRESS:
STREET 1: C/O G1 THERAPEUTICS, INC.
STREET 2: 700 PARK OFFICES DRIVE, SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER NAME:
FORMER CONFORMED NAME: Bailey John F. (Jack) Jr.
DATE OF NAME CHANGE: 20200310
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: G1 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001560241
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263648180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-213-9835
MAIL ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: G-Zero Therapeutics, Inc.
DATE OF NAME CHANGE: 20121012
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2023-01-03
false
0001560241
G1 Therapeutics, Inc.
GTHX
0001806147
Bailey John E. (Jack) Jr.
700 PARK OFFICES DRIVE, SUITE 200
RESEARCH TRIANGLE PARK
NC
27709
true
true
false
false
President and CEO
Common Stock
2023-01-03
4
A
false
80700.00
0.00
A
313908.00
D
Common Stock
2023-01-03
4
S
false
32019.00
5.8544
D
281889.00
D
Common Stock
2023-01-04
4
S
false
5607.00
5.5756
D
276282.00
D
Stock Options (Right to buy)
5.73
2023-01-03
4
A
false
161300.00
0.00
A
2033-01-03
Common Stock
161300.00
161300.00
D
Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Each RSU represents a contingent right to receive one share of Issuer common stock.
Represents (i) 44,986 shares of common stock; (ii) 142,222 RSUs from award granted on January 1, 2021; (iii) 46,000 RSUs from award granted on January 3, 2022; and (iv) 80,700 RSUs from award granted on January 3, 2023.
The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
The price represents the weighted average price with a low of $5.77 and a high of $5.94. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents (i) 84,078 shares of common stock; (ii) 71,111 RSUs from award granted on January 1, 2021; (iii) 46,000 RSUs from award granted on January 3, 2022; and (iv) 80,700 RSUs from award granted on January 3, 2023.
The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents (i) 89,971 shares of common stock; (ii) 71,111 RSUs from award granted on January 4, 2021; (iii) 34,500 RSUs from award granted on January 3, 2022; and (iv) 80,700 RSUs from award granted on January 3, 2023.
The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Note: On January 3, 2023, the reporting person was also granted performance-based restricted stock units that are subject to material conditions beyond the reporting person's control, and, therefore, not considered derivative securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and excluded from this report.
/s/ James Stillman Hanson, attorney-in-fact
2023-01-05
EX-24
2
poajohnbailey2020.txt
POWER OF ATTORNEY
POWER OF ATTORNEY
Know all by these present, that the undersigned hereby
constitutes and appoints each of James Stillman Hanson, General
Counsel, of G1 Therapeutics, Inc. (the "Company"), Jennifer Moses,
Chief Financial Officer of the Company, Sandi James, Director,
Legal, of the Company, and Megan N. Gates, Hana M. Sahdev, Troy R.
Nichols, Anne T. Leland, Brenda L. Meyette and Jacquelyn Cannata of
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly,
with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned, forms and
authentication documents for EDGAR Filing Access;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to
complete and execute any such forms and authentication
documents;
(3) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director and/or 10%
shareholder of the Company, Forms 3, 4 and 5 in accordance
with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder;
(4) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to
complete and execute any such Form 3, 4 or 5 and timely
file such form with the United States Securities and
Exchange Commission and any stock exchange or similar
authority; and
(5) take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-
in-fact, may be of benefit to, in the best interests of,
or legally required by the undersigned, it being
understood that the documents executed by such attorney-
in-fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain
such terms and conditions as such attorney-in-fact may
approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all
intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do
or cause to be done by virtue of this power of attorney and the rights
and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed on March 5, 2020.
/s/ John E. (Jack) Bailey Jr.
John E. (Jack) Bailey Jr.